- Home
- ENOV vs DNLI Comparison
ENOV vs DNLI Comparison
Compare ENOV & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENOV
- DNLI
- Stock Information
- Founded
- ENOV 1995
- DNLI 2013
- Country
- ENOV United States
- DNLI United States
- Employees
- ENOV N/A
- DNLI N/A
- Industry
- ENOV Fluid Controls
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENOV Industrials
- DNLI Health Care
- Exchange
- ENOV Nasdaq
- DNLI Nasdaq
- Market Cap
- ENOV 2.1B
- DNLI 2.1B
- IPO Year
- ENOV 2008
- DNLI 2017
- Fundamental
- Price
- ENOV $32.35
- DNLI $11.83
- Analyst Decision
- ENOV Buy
- DNLI Strong Buy
- Analyst Count
- ENOV 4
- DNLI 16
- Target Price
- ENOV $58.50
- DNLI $37.57
- AVG Volume (30 Days)
- ENOV 837.4K
- DNLI 1.4M
- Earning Date
- ENOV 05-01-2025
- DNLI 05-06-2025
- Dividend Yield
- ENOV N/A
- DNLI N/A
- EPS Growth
- ENOV N/A
- DNLI N/A
- EPS
- ENOV N/A
- DNLI N/A
- Revenue
- ENOV $2,107,623,000.00
- DNLI N/A
- Revenue This Year
- ENOV $7.09
- DNLI N/A
- Revenue Next Year
- ENOV $6.38
- DNLI $373.37
- P/E Ratio
- ENOV N/A
- DNLI N/A
- Revenue Growth
- ENOV 23.45
- DNLI N/A
- 52 Week Low
- ENOV $33.73
- DNLI $12.05
- 52 Week High
- ENOV $62.79
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- ENOV 25.13
- DNLI 33.62
- Support Level
- ENOV $36.43
- DNLI $12.05
- Resistance Level
- ENOV $38.56
- DNLI $14.83
- Average True Range (ATR)
- ENOV 1.39
- DNLI 0.90
- MACD
- ENOV -0.42
- DNLI 0.00
- Stochastic Oscillator
- ENOV 5.98
- DNLI 2.98
About ENOV Enovis Corporation
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.